Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02492620
Other study ID # 05D
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2015
Est. completion date November 2017

Study information

Verified date July 2018
Source Denver Nephrologists, P.C.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy.


Description:

This is an up to 50 week, phase 3, clinical trial in patients with estimated glomerular filtration rate (eGFR) ≤ 20 ml/min/1.73m2. It will be comprised of an up to 36-week non-dialysis period (NDP), or until such time as subjects require renal replacement therapy (RRT) with dialysis when they will immediately roll into a 12-week dialysis period (DP). The study will consist of up to 16 clinic visits over a maximum period of 50 weeks. There will be a screening period of up to 14 days after which subjects will be randomized into the NDP in a 2:1 ratio to receive either FC (n=150) or SOC (n=75). Each eligible participant will be randomized to either fixed dose open-label ferric citrate (FC) or standard of care (SOC) treatment. Participants randomized to SOC will receive care directed by their primary nephrologist throughout the study duration with the only restriction being that they cannot receive treatment with FC during the NDP or DP. Participants randomized to FC will receive it throughout the study duration.

220 participants were screened to randomize 200 subjects 2:1 (FC:SOC) into the NDP. It is anticipated that 35-45% of participants will reach the dialysis period (DP) during the 36 week follow up. Participants who initiate RRT with dialysis will enter the Dialysis Period (DP) during which those participants previously assigned to ferric citrate will continue to receive open-label ferric citrate and those previously assigned to SOC will receive open-label, non-FC phosphate binders at the discretion of their treating physician. During this period all participants will be treated to standard of care guidelines which suggest that if serum phosphate is above the upper limit of normal (4.5 mg/dL), it should be reduced. During the DP, dose of P binders, use of ESA, intravenous iron and blood transfusions will be at the discretion of the primary treating nephrologist. Participants assigned to the SOC treatment arm may not receive FC at any point during the study.

Only participants that begin permanent RRT with dialysis will be eligible to enter the 12 week DP. Participants that do not begin RRT after 9 months participation in the NDP will be deemed to have reach the end of study and have end of study procedures performed.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date November 2017
Est. primary completion date November 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Age >18 years at screening visit

2. Serum phosphate > or equal to 3.0 mg/dL obtained at screening

3. CKD with eGFR < or equal to 20 mL/min obtained at screening*

4. Hemoglobin (Hgb) >8.0 g/dL obtained at screening

5. TSAT <55% obtained at screening

6. Females of child bearing potential with negative serum pregnancy test obtained at screening

7. Willing and able to give written informed consent

8. Anticipated to have > or equal to 8 weeks prior to need for initiating RRT in the opinion of the investigator

Exclusion Criteria:

1. Liver enzymes (ALT/AST) >X3 times upper limit of normal at screening

2. Use of IV iron, blood transfusions or ESA agents within 2 weeks prior to the screening visit and prior to the Day 1 visit.

3. Evidence of acute kidney injury (i.e., no CKD) or planned need for RRT within 12 weeks of screening

4. Scheduled kidney transplant within 24 weeks of screening

5. Contra-indication to ferric citrate: iron overload syndrome, allergic reaction or known intolerance to ferric citrate

6. Clinically significant medical condition felt to interfere with tolerance of oral medication

7. Life expectancy < 6 months or confirmed conviction that subject does NOT want to initiate RRT despite a decline in kidney function

8. Active drug or alcohol dependence or abuse (excluding tobacco use or marijuana use) within the 12 months prior to screening (in the opinion of the PI)

9. Psychiatric disorder that interferes with the subject's ability to comply with the study protocol in the opinion of the PI

10. Any other medical condition that, in the opinion of the PI, renders the subject unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the subject

11. Inability to cooperate with study personnel or study procedures

12. Females who are pregnant or breastfeeding

13. Receiving or has received any investigational drug with in the past 30 days prior to the Day 1 visit

Study Design


Intervention

Drug:
Ferric Citrate
Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis

Locations

Country Name City State
United States Denver Nephrologists, P.C. Denver Colorado

Sponsors (2)

Lead Sponsor Collaborator
Denver Nephrologists, P.C. Keryx Biopharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Cumulative dose of erythropoietin analog Total dose of ESA received in units from baseline visit to 90 days post renal replacement Baseline visit to 90 days after starting renal replacement therapy
Other Cumulative dose of intravenous iron Total dose of intravenous iron received in units from baseline visit to 90 days post renal replacement Baseline visit to 90 days after starting renal replacement therapy
Primary Serum phosphate value prior to starting renal replacement therapy baseline
Secondary Serum hemoglobin prior to starting renal replacement therapy baseline
Secondary Serum transferrin saturation prior to starting renal replacement therapy baseline
Secondary Serum fibroblast growth factor 23 prior to starting renal replacement therapy baseline
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4